Dive into the archives.
- Biogen Receives FDA Fast Track Status for PEGylated Interferon Beta-1a
July 8, 2009
Biogen Idec (NASDAQ: BIIB) today announced the U.S. Food and Drug Administration (FDA) has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation for relapsing multiple sclerosis (RMS). Biogen Idec is currently enrolling patients in a global Phase III study evaluating the efficacy and safety of either bi-weekly or once-monthly injections of PEGylated interferon [...]
- Hot off the ENS Press…Rebif Autoinject Improves SC Delivery
MILAN, Italy
June 26, 2009
A new electronic, multidose, autoinjection device improves subcutaneous delivery of interferon beta (IFNB)-1a in patients with relapsing multiple sclerosis (MS), according to a study presented here at the 19th Meeting of the European Neurological Society (ENS2009).
Virginia Devonshire, MD, Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, presented [...]
- Teva completes enrollment in second Phase III trial
Jun 26, 2009 (Datamonitor via COMTEX) — Teva Pharmaceutical Industries, an Israeli generic pharmaceutical company, and Active Biotech, a Swedish pharmaceutical company, have completed patient enrollment for the second pivotal Phase III clinical trial, Bravo, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis.
// Bravo is a global clinical [...]
- Hot off the ENS Press: Immunomodulatory Treatment Improves Cognitive Function in PWMS
By Judith Moser, MD
MILAN, Italy — June 26, 2009 — Patients with relapsing-remitting multiple sclerosis (RRMS) who receive glatiramer acetate (GA) or interferon (IFN) beta show a reduction in cognitive impairment and relative stability of cognitive and affective variables at 2 years, according to the results of an observational study presented here at the 19th [...]
- Hot off the ENS Press: Cladribine Is Safe Overall in Patients With Multiple Sclerosis
MILAN, Italy — June 24, 2009 — According to a safety analysis of a study presented here at the 19th Meeting of the European Neurological Society (ENS), the incidence of treatment-emergent adverse events in the trial was comparable between 2 doses of cladribine and placebo in patients with multiple sclerosis (MS), with exceptions related to [...]
- Hot off the AAN Press: Laquinimod, New Data, Novel MOA
New Data Illustrate Novel Mechanism OF Action of Laquinimod, an Oral Compound for the Treatment of Multiple Sclerosis
-Researchers Demonstrate Immunomodulatory Effects of Laquinimod on Disease Activity
Jerusalem, Israel, Lund, Sweden and Seattle, Washington, April 28, 2009 – Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from several new [...]
- Hot off the AAN Press: Study Suggests Copaxone has Protective Effects
Long-Term Study with COPAXONE® Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
- New Data Presented at 61st Annual Meeting of the American Academy of Neurology -
JERUSALEM–New data presented today provided evidence that long-term treatment with COPAXONE® (glatiramer acetate injection) [...]
